ClinicalTrials.Veeva

Menu

Clinical Efficacy of OneTouch® Verio™IQ Meter (ECOVIQ)

F

Fundación Pública Andaluza Progreso y Salud

Status

Completed

Conditions

Diabetes Mellitus

Treatments

Device: Verio Pattern Alert® deactivated
Device: Verio Pattern Alert® activated

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Diabetes mellitus is one of the most prevalent disease in the western world. The control of glucose levels has a big impact in the prevention of diabetes complications. The measure of glucose levels in capillary blood with glucometers is the gold standard to measure and control the glucose levels. Nowadays the glucometers become to more precise and sophisticated devices. One of the most notables advance is the inclusion of software that cam predicts glucose trends. This software has not be tested in routine clinical practice.

Enrollment

90 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient diagnosed with diabetes mellitus 1 or 2
  • Treatment with insulin regimen during at least 12 months
  • Capability of performed 3 glucose measurement per day
  • Levels of glycated hemoglobin (A1C) less than 10%

Exclusion criteria

  • Patients diagnosed of mental disorders
  • Patients included in structured therapeutic health 6 months before the inclusion
  • Patients included in any clinical trial in the 4 months before the inclusion

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

90 participants in 2 patient groups

Verio Pattern Alert® activated
Experimental group
Description:
In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
Treatment:
Device: Verio Pattern Alert® activated
Verio Pattern Alert® deactivated
Active Comparator group
Description:
In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
Treatment:
Device: Verio Pattern Alert® deactivated

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems